Today: 20 May 2026
Diageo share price slides as Kenyan court bid targets $2.3bn Asahi deal
7 January 2026
2 mins read

Diageo share price slides as Kenyan court bid targets $2.3bn Asahi deal

London, Jan 7, 2026, 09:01 GMT — Regular session

  • Diageo shares fall after a Kenyan distributor seeks to block the EABL sale to Asahi
  • RBC lifts Diageo to “outperform” with a 2,000p target
  • Next catalysts: Nairobi hearing on Jan. 9; Diageo interim results on Feb. 25

Diageo (DGE.L) shares slipped on Wednesday after a Kenyan beer distributor lodged a lawsuit seeking to block the spirits maker’s planned $2.3 billion sale of East African Breweries (EABL) to Japan’s Asahi Holdings. The stock was down 1.4% at 1,620.5 pence by 0900 GMT, after trading between 1,606 and 1,649 pence, and sits about 2.6% above its 52-week low. Diageo did not immediately respond to a request for comment.

The court challenge lands as investors weigh Diageo’s push to simplify its portfolio and strengthen its balance sheet. Diageo, maker of Johnnie Walker whisky and Guinness, agreed on Dec. 17 to sell its 65% stake in EABL to Asahi for $2.3 billion, valuing the business at about $4.8 billion, with completion slated for the second half of 2026. “This transaction delivers both significant value for Diageo shareholders and accelerates our commitment to strengthen the balance sheet,” interim chief executive Nik Jhangiani said at the time. Reuters

Bia Tosha Distributors Ltd, which distributes products for Diageo’s Kenyan unit, asked the court to suspend the share sale until a separate case it filed in 2016 is resolved, according to court documents. “If they succeeded in disposing their only asset in Kenya, we will not be able to execute a judgment against Diageo,” said Ken Kiplagat, a legal representative for Bia Tosha, adding the court had set a hearing for Friday, Jan. 9. Investing.com

The legal headline follows a more upbeat broker call a day earlier. RBC Capital Markets upgraded Diageo to “outperform” from “sector perform” and kept its cash-flow-based price target at 2,000 pence, roughly 23% above the latest price. “We think that reviving the neglected mainstream is the key to Diageo rediscovering sustainable volume growth,” RBC said, while flagging a hit to profitability: it expects margins to fall 210 basis points (2.1 percentage points) in 2027. Sharecast

A recent insider trade has also been in focus as the stock hovers near lows. Diageo said chief commercial officer Dayalan Nayager bought 28,960 shares at £16.04 each on Dec. 30, according to a regulatory announcement.

For traders, the near-term question is whether the Kenyan litigation triggers any delay or interim restrictions on the transaction, and whether Diageo addresses the court filing. The deal’s timetable and conditions matter because the sale proceeds underpin part of the group’s plan to reduce leverage and sharpen its focus.

The next scheduled company update is Diageo’s interim results on Feb. 25 for the six months ended Dec. 31. Investors are likely to focus on any refresh to guidance, cash generation and progress on disposals and cost actions.

Risks run in both directions. Court action or regulatory hurdles could extend the closing timeline and push back proceeds, while the transaction structure also shifts Diageo’s exposure in East Africa toward long-term licensing and production agreements, which carry execution risk of their own.

Stock Market Today

  • Wall Street Price Targets: Lululemon Rated Buy, Hormel and Walker & Dunlop Marked Sell for May 2026
    May 20, 2026, 4:23 AM EDT. A recent StockStory analysis highlights Wall Street price targets for May 2026, identifying one stock recommended to buy and two to sell. Lululemon (NASDAQ:LULU) is rated a buy with a projected 47.9% return, supported by strong fundamentals. Conversely, Hormel Foods (NYSE:HRL), known for SPAM, and Walker & Dunlop (NYSE:WD) face selling pressure despite upside targets of 33.2% and 29.6%, respectively. Hormel battles declining unit sales and shrinking earnings, while Walker & Dunlop suffers from falling net interest income and equity erosion. Investors should weigh these fundamentals against price target optimism before making decisions.

Latest articles

Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

20 May 2026
Meiwu Technology shares jumped 97% to $4.75 Tuesday and rose another 12% premarket after the company raised $15.65 million in a private share sale to fund an AI skincare platform. The rally follows a 1-for-100 reverse share split in April and earlier $14 million direct offering. Meiwu warned its new platform is early-stage and faces regulatory risks.
Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results

Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results

20 May 2026
Astera Labs shares rose 13.3% to $244.26 on Tuesday after management outlined a faster ramp for its Scorpio X fabric switches and optical networking tied to Nvidia’s NVLink Fusion. The move followed presentations at J.P. Morgan’s tech conference and comes ahead of Nvidia’s earnings Wednesday. Astera’s first-quarter revenue jumped 93% to $308.4 million, with second-quarter guidance above analyst forecasts.
Snowflake Shares Rise Ahead of Results With AI Demand in Focus

Snowflake Shares Rise Ahead of Results With AI Demand in Focus

20 May 2026
Snowflake shares climbed 3.2% to $169.55 Tuesday after BofA Securities raised its price target to $205 and predicted strong fiscal Q1 results next week. Mizuho Securities channel checks indicated continued demand for Snowflake’s data and AI products. The company reports earnings after the market closes May 27. Recent deals include a $400 million contract and partnerships with OpenAI and Anthropic.
Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Previous Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop